drugset
drugset / Trial / NCT00387153

Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

NCT00387153 ↗

Phase 1 Terminated 8 enrolled Myriad Therapeutics, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1 Open-label treatment with MPC-2130 for subjects with refractory cancer.

Timeline

Start
2005-08
Primary completion
2006-10
Completion
2006-10

Outcome

Outcome not reported

Stopped (Enrollment): “Last subject enrolled experienced bradycardia; study was terminated by Sponsor.”

Drugs

EvaluationDrugModalityDoseRoute
Subject MPC-2130 Unknown 10 mg/ml Intravenous

Indications

cancer